HK1206283A1 - Treatment of multiple sclerosis with anti-cd19 antibody -cd19 - Google Patents

Treatment of multiple sclerosis with anti-cd19 antibody -cd19

Info

Publication number
HK1206283A1
HK1206283A1 HK15107127.4A HK15107127A HK1206283A1 HK 1206283 A1 HK1206283 A1 HK 1206283A1 HK 15107127 A HK15107127 A HK 15107127A HK 1206283 A1 HK1206283 A1 HK 1206283A1
Authority
HK
Hong Kong
Prior art keywords
antibody
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
HK15107127.4A
Other languages
English (en)
Chinese (zh)
Inventor
Ronald Herbst
Volker Armin Knappertz
Laura Lee Carter
Yue Wang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1206283A1 publication Critical patent/HK1206283A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107127.4A 2012-03-12 2015-07-27 Treatment of multiple sclerosis with anti-cd19 antibody -cd19 HK1206283A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609704P 2012-03-12 2012-03-12
PCT/US2013/030247 WO2013138244A2 (fr) 2012-03-12 2013-03-11 Traitement de la sclérose en plaques par un anticorps anti-cd19

Publications (1)

Publication Number Publication Date
HK1206283A1 true HK1206283A1 (en) 2016-01-08

Family

ID=49161934

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107127.4A HK1206283A1 (en) 2012-03-12 2015-07-27 Treatment of multiple sclerosis with anti-cd19 antibody -cd19

Country Status (11)

Country Link
US (1) US20150044168A1 (fr)
EP (1) EP2827902A4 (fr)
JP (1) JP2015515456A (fr)
KR (1) KR20140148411A (fr)
CN (1) CN104640560A (fr)
AU (1) AU2013232386A1 (fr)
CA (1) CA2866943A1 (fr)
HK (1) HK1206283A1 (fr)
MX (1) MX2014010987A (fr)
RU (1) RU2014141056A (fr)
WO (1) WO2013138244A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
WO2017015783A1 (fr) * 2015-07-24 2017-02-02 Shanghai Sidansai Biotechnology Co., Ltd Anticorps humanisé anti-cd19 et utilisation associée
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
EP3959241A4 (fr) * 2019-04-24 2023-01-25 Viela Bio, Inc. Utilisation d'un anticorps anti-cd19 pour traiter une maladie auto-immune

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648512A4 (fr) * 2003-07-31 2009-01-21 Immunomedics Inc Anticorps anti-cd19
WO2005117978A2 (fr) * 2004-06-04 2005-12-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
MX2009002414A (es) * 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
KR20110125664A (ko) * 2009-03-06 2011-11-21 메디뮨 엘엘씨 인간화된 항-ｃｄ19 항체 제형

Also Published As

Publication number Publication date
MX2014010987A (es) 2015-03-03
RU2014141056A (ru) 2016-05-10
WO2013138244A3 (fr) 2014-12-24
US20150044168A1 (en) 2015-02-12
EP2827902A2 (fr) 2015-01-28
KR20140148411A (ko) 2014-12-31
WO2013138244A8 (fr) 2014-09-18
AU2013232386A1 (en) 2014-10-16
CA2866943A1 (fr) 2013-09-19
CN104640560A (zh) 2015-05-20
JP2015515456A (ja) 2015-05-28
AU2013232386A8 (en) 2014-10-23
WO2013138244A2 (fr) 2013-09-19
EP2827902A4 (fr) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2723384A4 (fr) Traitement de protéinopathies
HK1207583A1 (en) Use of biotin for the treatment of multiple sclerosis
ZA201406082B (en) Use of ccr3-inhibitors
IL237460B (en) Treatment of post-traumatic stress disorder with an isolated microbacterium
EP2906580A4 (fr) Traitement de la sclérose latérale amyotrophique
HK1211986A1 (en) Platelet targeted treatment
EP2881113A4 (fr) Nouvelle application de la pogostone
HK1206283A1 (en) Treatment of multiple sclerosis with anti-cd19 antibody -cd19
HK1204629A1 (en) Treatment of mucositis with immunoglobulin
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2892529A4 (fr) Utilisations de (-)-perhexiline
GB201207907D0 (en) Treatment of depression
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
GB201218263D0 (en) Treatment of autism
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201321600D0 (en) Method of cleaning
TWM433525U (en) Structure of calorifier
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment